ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
61,197.64
-3.11%
S&P 500
5,464.62
-0.16%
Dow Jones
39,150.33
0.00%
US Dollar vs Yen
159.4985
-0.23%
Brent Oil
84.815
0.95%
Registration Strip Icon for charts 登録してリアルタイムのチャート、分析ツール、価格を入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Enliven Therapeutics Inc (ELVN)

  7. Enliven Therapeutics Inc (ELVN) ニュース

ELVN

Enliven Therapeutics (ELVN)

Enliven Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:ELVN
日付受信時刻ニュースソース見出しコード企業名
2024/06/1906 : 12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELVNEnliven Therapeutics Inc
2024/06/1107 : 46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELVNEnliven Therapeutics Inc
2024/06/0105 : 05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELVNEnliven Therapeutics Inc
2024/05/3106 : 56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELVNEnliven Therapeutics Inc
2024/05/3106 : 54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELVNEnliven Therapeutics Inc
2024/05/3005 : 08Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ELVNEnliven Therapeutics Inc
2024/05/3005 : 06Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ELVNEnliven Therapeutics Inc
2024/05/3005 : 05GlobeNewswire Inc.Enliven Therapeutics to Present at Two Upcoming Investor ConferencesNASDAQ:ELVNEnliven Therapeutics Inc
2024/05/2906 : 45Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ELVNEnliven Therapeutics Inc
2024/05/2906 : 29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ELVNEnliven Therapeutics Inc
2024/05/1708 : 29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELVNEnliven Therapeutics Inc
2024/05/1505 : 15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ELVNEnliven Therapeutics Inc
2024/05/1505 : 10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELVNEnliven Therapeutics Inc
2024/05/1505 : 05GlobeNewswire Inc.Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business UpdateNASDAQ:ELVNEnliven Therapeutics Inc
2024/05/1408 : 35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELVNEnliven Therapeutics Inc
2024/05/0909 : 40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELVNEnliven Therapeutics Inc
2024/05/0807 : 58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELVNEnliven Therapeutics Inc
2024/04/1120 : 55GlobeNewswire Inc.Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid LeukemiaNASDAQ:ELVNEnliven Therapeutics Inc
2024/04/1005 : 05GlobeNewswire Inc.Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of DirectorsNASDAQ:ELVNEnliven Therapeutics Inc
2024/03/2905 : 05GlobeNewswire Inc.Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024NASDAQ:ELVNEnliven Therapeutics Inc
2024/03/1921 : 30GlobeNewswire Inc.Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline UpdatesNASDAQ:ELVNEnliven Therapeutics Inc
2024/03/1505 : 05GlobeNewswire Inc.Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business UpdateNASDAQ:ELVNEnliven Therapeutics Inc
2024/03/0909 : 52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELVNEnliven Therapeutics Inc
2024/03/0707 : 43Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ELVNEnliven Therapeutics Inc
2024/03/0507 : 55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELVNEnliven Therapeutics Inc
2024/03/0107 : 27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELVNEnliven Therapeutics Inc
2024/02/2806 : 05GlobeNewswire Inc.Enliven Therapeutics to Present at TD Cowen’s 44th Annual Health Care ConferenceNASDAQ:ELVNEnliven Therapeutics Inc
2024/02/2806 : 02Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ELVNEnliven Therapeutics Inc
2024/02/2109 : 35Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:ELVNEnliven Therapeutics Inc
2024/02/2109 : 27Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:ELVNEnliven Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ELVN

最近閲覧した銘柄

CCOM
SILVER
SILVER
CCOM
US500
US 500
AMEX
XLF
Financial Select Sector
NYSE
AXP
American Express
NYSE
MRK
Merck
NYSE
CVX
Chevron
FX
USDJPY
US Dollar vs Yen
NASDAQ
GOOGL
Alphabet
NASDAQ
TSLA
Tesla
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NASDAQ
NVDA
NVIDIA
CCOM
US100
US Tech 100
CCOM
US30
US 30
COIN
ETHUSD
Ethereum
USOTC
ADDYY
Adidas (QX)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有